| 非小细胞肺癌新辅助靶向及免疫治疗研究进展和展望 |
| |
| 引用本文： | 徐嵩,赵世康,任凡,任典,王延烨,宋作庆,陈军.非小细胞肺癌新辅助靶向及免疫治疗研究进展和展望[J].中国肿瘤临床,2020,47(6):299-303. |
| |
| 作者姓名： | 徐嵩 赵世康 任凡 任典 王延烨 宋作庆 陈军 |
| |
| 作者单位： | 天津医科大学总医院肺部肿瘤外科, 天津市肺癌研究所, 天津市肺癌转移与肿瘤微环境实验室(天津市 300052) |
| |
| 基金项目： | 国家自然科学基金项目81772464天津自然科学基金重点项目17JCZDJC36200天津市科技局重大疾病防治科技重大专项19ZXDBSY00060 |
| |
| 摘 要： | 肺癌是全球发病率和死亡率最高的恶性肿瘤。近年来,随着新型药物的出现和治疗模式的优化,肺癌患者的预后已有一定改善。新辅助治疗是指对潜在可接受手术切除的患者,先给予术前抗肿瘤治疗后再行手术治疗。新辅助治疗通过术前治疗可以缩小肿瘤体积,降低肿瘤分期;并且可以杀灭患者机体中循环肿瘤细胞及微转移病灶,令患者远期生存获益。靶向治疗及免疫治疗已被应用于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的一线治疗。因此,有临床试验尝试将以上两种治疗手段应用于早期可切除NSCLC患者的新辅助治疗。本文针对新辅助靶向及免疫治疗对早期可切除NSCLC患者的疗效、治疗中的潜在风险予以综述,并探讨新辅助治疗的未来发展方向。
|
| 关 键 词： | 非小细胞肺癌 新辅助治疗 靶向治疗 免疫治疗 |
| 收稿时间： | 2020-02-16 |
Progress and prospects of neoadjuvant target therapy and immunotherapy for non-small cell lung cancer |
| |
| Song Xu,Shikang Zhao,Fan Ren,Dian Ren,Yanye Wang,Zuoqing Song,Jun Chen.Progress and prospects of neoadjuvant target therapy and immunotherapy for non-small cell lung cancer[J].Chinese Journal of Clinical Oncology,2020,47(6):299-303. |
| |
| Authors: | Song Xu Shikang Zhao Fan Ren Dian Ren Yanye Wang Zuoqing Song Jun Chen |
| |
| Affiliation: | Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China |
| |
| Abstract: | Of all malignant tumors, lung cancer has the highest morbidity and mortality worldwide. In recent years, with the emergence of new drugs and the optimization of treatment models, the prognosis of patients with lung cancer has improved. Neoadjuvant therapy refers to the treatment provided to patients with a resectable tumor prior to surgery. This treatment can reduce tumor volume and downstage the tumor; it is also reported to remove circulating tumor cells and micrometastasis, and enable patients to achieve longer survival. Targeted therapy and immunotherapy have been used as the first-line treatment for non-small cell lung cancer (NSCLC). Some clinical trials have proposed the use of targeted therapy and immunotherapy as neoadjuvant therapy. This review intends to summarize the efficacies and potential risks of neoadjuvant targeted therapy and immunotherapy in patients with NSCLC and to discuss future developments in neoadjuvant therapy. |
| |
| Keywords: | non-small cell lung cancer neoadjuvant therapy targeted therapy immunotherapy |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
